Positive results of a colon cancer study conducted by Exact Sciences prompt the CEO of competitor Guardant Health to publicly ...

A victory for the Federal Trade Commission, set to conclude Tuesday, could pave the way for an Amazon buying spree. The deal further expands Carlyle's push into asset-based finance.

The world's largest music company laid out a vision to drive revenue growth through 2028. The FTC report said the companies responsible for controlling spending on drugs were sometimes steering ...

Researchers investigated the relationship between the degree of food processing and type 2 diabetes risk, including which ...

Researchers with the Chinese Academy of Sciences have figured out why beer tastes better cold. It's all about ethanol, the ...

As it works to diversify its methods for catching early cases of colorectal cancer, Exact Sciences has put forward clinical ...

Analyst Brandon Couillard of Wells Fargo maintained a Buy rating on Exact Sciences (EXAS – Research Report), retaining the price target ...

Analyst Tycho Peterson of Jefferies assigned a Buy rating on Exact Sciences (EXAS – Research Report), with a price target of $84.00. Tycho Peterson has given his Buy rating due to a combination ...

Data presented show sensitivities of 88% for colorectal cancer and 31% for advanced precancerous lesions at 90% specificity Scientific insights reflect Exact Sciences’ commitment to closing the ...

Exact Sciences, which has for years sold a stool-based colon cancer test, on Monday announced that a blood-based test it’s developing showed promise in accurately detecting the disease.

On Monday, BTIG updated its outlook on Exact Sciences Corp (NASDAQ:EXAS), increasing the price target to $82 from the previous $70 while reiterating a Buy rating on the stock. The adjustment ...